Antiepileptic drug sales will strengthen through 2035, anchored by oral administration at 62.2% share of the administration mode segment in 2025. Second generation drugs account for 53.4% share of the drug generation segment in 2025. The market is expected to reach USD 19.7 billion in 2025 and USD 30.0 billion by 2035.